Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD (NBV, JGH, KED, ASH); National Clinician Scholars Program at the Corporal Michael J. Crescenz VA Medical Center, University of Pennsylvania, Philadelphia, PA (APT); Ashley Addiction Treatment, Havre de Grace, MD (JGH, ASH).
Send correspondence to Neil B. Varshneya, PhD, Behavioral Biology Research Center, 5510 Nathan Shock Drive, Baltimore, MD, 21224-6823. E-mail: [email protected].
Received 26 July, 2021
Accepted 3 September, 2021
Research reported in this publication was financially supported by the National Institute on Drug Abuse of the National Institutes of Health (T32DA007209 [NBV] and UG3DA048734 [ASH, KED]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, Johns Hopkins University, University of Pennsylvania, Ashley Addiction Treatment, or NLW Partners, LLC.
The authors report no conflicts of interest.
Supplemental digital content is available for this article. Direct URL citation appears in the printed text and is provided in the HTML and PDF versions of this article on the journal's Web site (www.journaladdictionmedicine.com).
